Key result
Tyrosine kinase inhibitors induce atrial fibrillation through metabolic shifts and mitochondrial dysfunction.
Why the study?
Clinical use of TKIs has been hindered by atrial fibrillation, with recent studies implicating mitochondrial dysfunction and cardiac substrate utilization shifts in its mechanisms.
This review highlights the role of mitochondrial dysfunction and altered cardiac substrate utilization in TKI-induced atrial fibrillation, identifying potential therapeutic targets to mitigate this adverse effect.
Answers are grounded in this paper and cite their sources.
May warrant AF surveillance on TKIs; leaves open trials of mitochondrial-targeted prevention.
Tyrosine kinase inhibitors (TKIs) are a novel category of antitumor agents with remarkable efficacy in extending patient survival. However, clinical use of TKIs has been hindered by the major adverse effect of atrial fibrillation (AF). Recent studies have revealed that TKIs induce metabolic alterations and remodeling in cardiomyocytes, thus perturbing energy metabolism. Specifically, mitochondrial dysfunction and shifts in cardiac substrate utilization have been implicated in the mechanisms underlying TKI-induced AF. In light of these findings, this article reviews the energy metabolism-associated pathways involved in TKI-induced AF, identifies precise therapeutic targets for managing this condition, and discusses evidence that may contribute to the development of novel TKIs without cardiac adverse effects.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) conducted a review in TKI-induced Atrial Fibrillation. Tyrosine Kinase Inhibitors (TKIs) was evaluated. Tyrosine kinase inhibitors induce atrial fibrillation through metabolic alterations, mitochondrial dysfunction, and shifts in cardiac substrate utilization.
Synapse has enriched 10 related papers. Consider them for comparative context: